Editorial companion

What stands out

Mike Doustdar, Novo Nordisk's CEO, unveiled a 2030 strategy stressing diversification away from Wegovy, the company's blockbuster weight-loss medicine. Shares fell after the plan, reflecting investor concern about heavy dependence on one product and the prospect of new spending or slower growth. The clip is notable because a CEO publicly reframing the firm's growth drivers alters expectations for margins and capital allocation, and makes Novo's road to sustaining top-line growth more uncertain as competitors advance.